Early intervention with almotriptan: Results of the AEGIS trial (AXERT® early migraine intervention study)

Headache

Volumn 47, Issue 2, 2007, Pages 189-198

  Mathew, Ninan T ^a   Finlayson, Gary ^b   Smith, Timothy R ^c   Cady, Roger K ^d   Adelman, James ^e   Mao, Lian ^b   Wright, Pamela ^b   Greenberg, Steven J ^b  

^a Houston Headache Clinic   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c Ryan Headache Center   (United States)

^d HEADACHE CARE CENTER   (United States)

^e Headache Wellness Center   (United States)

Author keywords

Almotriptan; Early intervention; Efficacy; Migraine; Tolerability

Indexed keywords

ALMOTRIPTAN; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA AND VOMITING; PAIN ASSESSMENT; PERSONAL DIGITAL ASSISTANT; PHONOPHOBIA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PAIN; PROSPECTIVE STUDIES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; UNITED STATES;

EID: 33846947572     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2006.00686.x     Document Type: Article

References (31)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Menken M, Munsat TL, Toole JF. The global burden of disease study: Implications for neurology. Arch Neurol. 2000;57:418-420.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: Disability and economic costs. Arch Intern Med. 1999;159:813-818.
4. Silberstein SD. Practice parameter: Evidence-based guidelines formigraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:313-320.
5. Goadsby PJ. The pharmacology of headache. Prog Neurobiol. 2000;62:509-525.
6. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitization. Ann Neurol. 2004;55:27-36.
7. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: A race against the development of cutaneous allodynia. Ann Neurol. 2004;55:19-26.
8. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: Second ed. Cephalalgia. 2000;20:765-786.
9. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: Retrospective analyses of data from three clinical trials. Clin Ther. 2000;22:1035-1048.
10. The International 311C90 Long-term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache. 1998;38:173-183.
11. Cady RK, Lipton RB, Hall C, Stewart WF, O'Quinn S, Gutterman D. Treatment of mild headache in disabled migraine sufferers: Results of the Spectrum Study. Headache. 2000;40:792-797.
12. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: The sooner the better. Headache. 2002;42:28-31.
13. Mathew NT. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache. 2003;43:1075-1079.
14. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache. 2004;44:318-322.
15. Winner P, Landy S, Richardson M, Ames M. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: A pooled analysis of data from six clinical trials. Clin Ther. 2005;27:1785-1794.
16. Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of amigraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 2004;24:925-933.
17. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: A placebo-controlled study. Headache. 2004;44:669-673.
18. Klapper J, Lucas C, Rosjo O, Charlesworth B. Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia. 2004;24:918-924.
19. Cady RK, Elkind A, Goldstein J, Keywood C. Randomized, placebo-controlled comparison of early use of frovatriptan in amigraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004;20:1465-1472.
20. Loder E, Freitag FG, Adelman J, Pearlman S, Abu-Shakra S. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo- controlled trial. Curr Med Res Opin. 2005;21:381-389.
21. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia. 2005;25:735-742.
22. Foley KA, Cady RK, Martin V, et al. Treating early versus treating mild: Timing of migraine prescription medications among patients with diagnosed migraine. Headache. 2005;45:538-545.
23. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: Concerns about side effects may delay treatment. Headache. 2003;43:36-44.
24. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
25. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract. 2006;60:698-706.
26. Freitag FG, Greenberg S, Unger JR, Finlayson G, Diamond ML, Fisher A, Hulihan J. Effect of time to treatment on headache duration: Interim results from AIMS: AXERT® 12.5 mg time vs Intensity Migraine Study. Headache. 2005;45:806.
27. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290:2443-2454.
28. Sheftell FD, Feleppa M, Tepper SJ, et al. Assessment of adverse events associated with triptans-methods of assessment influence the results. Headache. 2004;44:978-982.
29. Dahlöf CGH, Dodick DW, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache. 2002;42:99-113.
30. Dodick DW. Oral almotriptan in the treatment of migraine: Safety and tolerability. Headache. 2001;41:449-455.
31. Ferrrari MD. Should we advise patients to treat migraine attacks early? Cephalalgia. 2004;24:915-917.